ArticleIranian journal of biotechnology2026
Kremen2 Promotes Colorectal Cancer Progression by Activating the EGFR/JAK2/STAT3 Signaling Pathway.
Article in Iranian journal of biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Kremen2 is a key regulator of the Wnt/β-catenin signaling pathway, implicating in tumorigenesis. While its role in colorectal cancer (CRC) remains largely unexplored. Objectives: This study aimed to investigate the biological function of Kremen2 in colorectal cancer and to elucidate the molecular mechanisms underlying its involvement in cancer cell proliferation and metastasis. Materials and Methods: We examined Kremen2 expression in human colon cancer cell lines (SW480 and HCT116) and compared it to normal intestinal epithelial cells (NCM460). A Kremen2-knockdown cell model was established to assess the impact on cell proliferation and migration using standard in vitro assays. The associated signaling pathways were analyzed to determine mechanistic changes following Kremen2 suppression. Results: Kremen2 expression was significantly elevated in colon cancer cell lines compared to normal controls. Knockdown of Kremen2 in HCT116 cells led to reduced cell viability and impaired migratory ability. Mechanistically, silencing Kremen2 resulted in downregulation of the EGFR/JAK2/STAT3 signaling pathway. Conclusions: Kremen2 promotes colorectal cancer cell proliferation and migration through activation of the EGFR/JAK2/STAT3 pathway. These findings identify Kremen2 as a potential therapeutic target in CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.